A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis

Endocrine-Related Cancer

Volumn 14, Issue 2, 2007, Pages 433-444

  Johanson, Viktor ^a   Ahlman, Håkan ^a   Bernhardt, Peter ^a   Jansson, Svante ^a   Kölby, Lars ^a   Persson, Fredrik ^a   Stenman, Göran ^a   Swärd, Christina ^a   Wängberg, Bo ^a   Stridsberg, Mats ^b   Nilsson, Ola ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; CHROMOGRANIN A; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN RET; PROTEIN TYROSINE KINASE; VANDETANIB; VASCULOTROPIN RECEPTOR;

AGED; ANAMNESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CHROMOSOME ANALYSIS; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG MEGADOSE; FEMALE; GENE MUTATION; GENETIC DISORDER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; SPECTRAL KARYOTYPING; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; TUMOR REGRESSION; TUMOR VOLUME;

AGED; ANIMALS; CALCITONIN; CARCINOMA, MEDULLARY; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CHROMOGRANIN A; DISEASE MODELS, ANIMAL; HUMANS; KARYOTYPING; MALE; MICE; MICE, NUDE; MUTATION; PIPERIDINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-RET; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; THYROID NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34547785538     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-06-0033     Document Type: Article

References (46)

1. Brauckhoff M, Lorenz K, Ukkat J, Brauckhoff K, Gimm O & Dralle H 2004 Medullary thyroid carcinoma. Scandinavian Journal of Surgery 93 249-260.
2. Carlomagno F, Vitagliano D, Guida T, Napolitano M, Vecchio G, Fusco A, Gazit A, Levitzki A & Santoro M 2002a The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Research 62 1077-1082.
3. Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A & Santoro M 2002b ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Research 62 7284-7290.
4. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM & Santoro M 2006 BAY 43-9006 inhibition of oncogenic RET mutants. Journal of the National Cancer Institute 98 326-334.
5. Cohen MS, Hussain HB & Moley JF 2002 Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. Surgery 132 960-966.
6. Cooley LD, Elder FF, Knuth A & Gagel RF 1995 Cytogenetic characterization of three human and three rat medullary thyroid carcinoma cell lines. Cancer Genetics and Cytogenetics 80 138-149.
7. Cuccuru G, Lanzi C, Cassinelli G, Pratesi G, Tortoreto M, Petrangolini G, Seregni E, Martinetti A, Laccabue D, Zanchi C et al. 2004 Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma. Journal of the National Cancer Institute 96 1006-1014.
8. Druker BJ 2002 Perspectives on the development of a molecularly targeted agent. Cancer Cell 1 31-36.
9. Eng C 1999 RET proto-oncogene in the development of human cancer. Journal of Clinical Oncology 17 380-393.
10. Ezzat S, Huang P, Dackiw A & Asa SL 2005 Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. Clinical Cancer Research 11 1336-1341.
11. Gschwind A, Fischer OM & Ullrich A 2004 The discovery of receptor tyrosine kinases: targets for cancer therapy. Nature Reviews. Cancer 4 361-370.
12. Gustafson DL, Bradshaw-Pierce EL, Merz AL & Zirrolli JA 2006 Tissue distribution and metabolism of the tyrosine kinase inhibitor ZD6474 (Zactima) in tumor bearing nude mice following oral dosing. Journal of Pharmacology and Experimental Therapeutics 318 872-880.
13. Heymach JV 2005 ZD6474 - clinical experience to date. British Journal of Cancer 92 14-20.
14. Holden SN, Eckhardt SG, Basser R, de Boer R, Rischin D, Green M, Rosenthal MA, Wheeler C, Barge A & Hurwitz HI 2005 Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Annals of Oncology 16 1391-1397.
15. ISCN 1995 In An International System for Human Cytogenetic Nomenclature, Ed F Mitelman. Basel: S. Karger.
16. Jakobsen AM, Ahlman H, Wängberg B, Kölby L, Bengtsson M & Nilsson O 2002 Expression of synaptic vesicle protein 2 (SV2) in neuroendocrine tumours of the gastrointestinal tract and pancreas. Journal of Pathology 196 44-50.
17. Juweid M, Sharkey RM, Behr T, Swayne LC, Herskovic T, Pereira M, Rubin AD, Hanley D, Dunn R, Siegel J et al. 1996 Radioimmunotherapy of medullary thyroid cancer with iodine-131-labeled anti-CEA antibodies. Journal of Nuclear Medicine 37 905-911.
18. Koch CA, Huang SC, Moley JF, Azumi N, Chrousos GP, Gagel RF, Zhuang Z, Pacak K & Vortmeyer AO 2001 Allelic imbalance of the mutant and wild-type RET allele in MEN 2A-associated medullary thyroid carcinoma. Oncogene 20 7809-7811.
19. Kodama Y, Asai N, Kawai K, Jijiwa M, Murakumo Y, Ichihara M & Takahashi M 2005 The RET proto-oncogene: a molecular therapeutic target in thyroid cancer. Cancer Science 96 143-148.
20. Kölby L, Bernhardt P, Swärd C, Johanson V, Ahlman H, Forssell-Aronsson E, Stridsberg M, Wängberg B & Nilsson O 2004 Chromogranin A as a determinant of midgut carcinoid tumour volume. Regulatory Peptides 120 269-273.
21. Krause DS & Van Etten RA 2005 Tyrosine kinases as targets for cancer therapy. New England Journal of Medicine 353 172-187.
22. Leboulleux S, Baudin E, Travagli JP & Schlumberger M 2004 Medullary thyroid carcinoma. Clinical Endocrinology 61 299-310.
23. Machens A, Gimm O, Hinze R, Hoppner W, Boehm BO & Dralle H 2001 Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. Journal of Clinical Endocrinology and Metabolism 86 1104-1109.
24. McCarty MF, Wey J, Stoeltzing O, Liu W, Fan F, Bucana C, Mansfield PF, Ryan AJ & Ellis LM 2004 ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. Molecular Cancer Therapeutics 3 1041-1048.
25. Moley JF, Debenedetti MK, Dilley WG, Tisell LE & Wells SA 1998 Surgical management of patients with persistent or recurrent medullary thyroid cancer. Journal of Internal Medicine 243 521-526.
26. Nilsson O, Kölby L, Wängberg B, Wigander A, Billig H, William-Olsson L, Fjälling M, Forssell-Aronsson E & Ahlman H 1998 Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours. British Journal of Cancer 77 632-637.
27. Nordkvist A, Mark J, Gustafsson H, Bang G & Stenman G 1994 Non-random chromosome rearrangements in adenoid cystic carcinoma of the salivary glands. Genes, Chromosomes and Cancer 10 115-121.
28. Öberg K & Stridsberg M 2000 Chromogranins as diagnostic and prognostic markers in neuroendocrine tumours. Advances in Experimental Medicine and Biology 482 329-337.
29. Pfragner R, Hofler H, Behmel A, Ingolic E & Walser V 1990 Establishment and characterization of continuous cell line MTC-SK derived from a human medullary thyroid carcinoma. Cancer Research 50 4160-4166.
30. Pfragner R, Wirnsberger G, Behmel A, Niederle B, Langle F, Roka R, Mandl A, Purstner P, Auner J & Tatzber F 1992 Biologic and cytogenetic characterization of three human medullary thyroid carcinomas in culture. Henry Ford Hospital Medical Journal 40 299-302.
31. Plaza Menacho I, de Groot JW, Links T, Plukker J, Eggen BJ & Hofstra R 2004 Re: inhibition of medullary thyroid carcinoma (MTC) cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. Surgery 135 240-241.
32. Pützer BM & Drosten M 2004 The RET proto-oncogene: a potential target for molecular cancer therapy. Trends in Molecular Medicine 10 351-357.
33. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA et al. 2001 KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Research 61 8118-8121.
34. Ryan AJ & Wedge SR 2005 ZD6474 - a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. British Journal of Cancer 92 S6-13.
35. Samaan NA, Schultz PN, Hickey RC, Goepfert H, Haynie TP, Johnston DA & Ordonez NG 1992 The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. Journal of Clinical Endocrinology and Metabolism 75 714-720.
36. Schlumberger M, Abdelmoumene N, Delisle MJ & Couette JE 1995 Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs Calcitonine (GETC). British Journal of Cancer 71 363-365.
37. Schrock E, du Manoir S, Veldman T, Schoell B, Wienberg J, Ferguson-Smith MA, Ning Y, Ledbetter DH, Bar-Am I, Soenksen D et al. 1996 Multicolor spectral karyotyping of human chromosomes. Science 273 494-497.
38. Skinner MA, Safford SD & Freemerman AJ 2003 RET tyrosine kinase and medullary thyroid cells are unaffected by clinical doses of STI571. Anticancer Research 23 3601-3606.
39. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A et al. 1989 Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 707-712.
40. Strock CJ, Park JI, Rosen M, Dionne C, Ruggeri B, Jones-Bolin S, Denmeade SR, Ball DW & Nelkin BD 2003 CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. Cancer Research 63 5559-5563.
41. Tisell LE, Ahlman H, Wängberg B, Hansson G, Mölne J, Nilsson O, Lindstedt G, Fjälling M & Forssell-Aronsson E 1997 Somatostatin receptor scintigraphy in medullary thyroid carcinoma. British Journal of Surgery 84 543-547.
42. Tisell LE, Odén A, Muth A, Altiparmak G, Mölne J, Ahlman H & Nilsson O 2003 The Ki67 index a prognostic marker in medullary thyroid carcinoma. British Journal of Cancer 89 2093-2097.
43. Warmuth M, Danhauser-Riedl S & Hallek M 1999 Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies. Annals of Hematology 78 49-64.
44. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL et al. 2002 ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Research 62 4645-4655.
45. Wells S, You YN, Lakhani V, Hou J, Langmuir P, Headley D, Skinner M, Morse M, Burch W & Schlumberger M 2006 A phase II trial of ZD6474 in patients with hereditary metastatic medullary thyroid cancer. Journal of Clinical Oncology 24 5533.
46. Wu LT, Averbuch SD, Ball DW, de Bustros A, Baylin SB & McGuire WP III 1994 Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Cancer 73 432-436.